WordNet

a salt or ester of tartaric acid
an alkaloid derived from ergot that is less toxic than ergot; causes constriction of blood vessels and is used to treat migraine

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/11/18 10:36:34」(JST)

wiki en

Ergotamine is an ergopeptine and part of the ergot family of alkaloids; it is structurally and biochemically closely related to ergoline. It possesses structural similarity to several neurotransmitters, and has biological activity as a vasoconstrictor.

It is used medicinally for treatment of acute migraine attacks (sometimes in combination with caffeine). Medicinal usage of ergot fungus began in the 16th century to induce childbirth, yet dosage uncertainties discouraged the use. It has been used to prevent post-partum haemorrhage (bleeding after childbirth). It was first isolated from the ergot fungus by Arthur Stoll at Sandoz in 1918 and marketed as Gynergen in 1921.^[4]

Mechanism of action[edit]

The mechanism of action of ergotamine is complex.^[5] The molecule shares structural similarity with neurotransmitters such as serotonin, dopamine, and epinephrine and can thus bind to several receptors acting as an agonist. The anti-migraine effect is due to constriction of the intracranial extracerebral blood vessels through the 5-HT_1B receptor, and by inhibiting trigeminal neurotransmission by 5-HT_1D receptors. Ergotamine also has effects on the dopamine and norepinephrine receptors. It's side effects are due mainly to it's action at the D2 dopamine and 5-HT_1A receptors.^[6]

Biosynthesis[edit]

Ergotamine is a secondary metabolite (natural product) and the principal alkaloid produced by the ergot fungus, Claviceps purpurea, and related fungi in the family Clavicipitaceae.^[7] Its biosynthesis in these fungi requires the amino acid L-tryptophan and dimethylallyl diphosphate. These precursor compounds are the substrates for the enzyme, dimethylallyl-tryptophan (DMAT) synthase, catalyzing the first step in ergot alkaloid biosynthesis, i.e., the prenylation of L-tryptophan. Further reactions, involving methyltransferase and oxygenase enzymes, yield the ergoline, lysergic acid. Lysergic acid (LA) is the substrate of lysergyl peptide synthetase, a nonribosomal peptide synthetase, which covalently links LA to the amino acids, L-alanine, L-proline, and L-phenylalanine. Enzyme-catalyzed or spontaneous cyclizations, oxygenations/oxidations, and isomerizations at selected residues precede, and give rise to, formation of ergotamine.^[8]

Drug uses[edit]

Ergotamine produces vasoconstriction peripherally as well as damages the peripheral epithelium. In high doses ergotamine is conducive to vascular stasis, thrombosis and gangrene. It can increase uterine contractivity and occasionally is used therapeutically immediately post-partum to decrease uterine bleeding. See also ergometrine.

Ergotamine continues to be prescribed for migraines.

Contraindications include: atherosclerosis, Buerger's syndrome, coronary artery disease, hepatic disease, pregnancy, pruritus, Raynaud's syndrome, and renal disease.^[9]

Availability & dosage[edit]

In America, the only commercially available preparation of ergotamine is the Cafergot® suppository tablet, which contains 2 mg of ergotamine with 100 mg caffeine. This preparation may either be used daily to prevent migraines or immediately following the aura/onset of pain to abort the migraine. The tablets are supplied in packages of 12 tablets.^[10]

Side effects[edit]

Ergotamine is associated with adverse effects that are significantly more severe than the effects of the triptans. These side effects, along with a decreased effectiveness compared to the triptans, explain why ergotamine is a rarely used abortive drug for the treatment of migraines. The side effects include GI tract irritation, tingling, angina, contraction of the uterus, damage to the endothelium, vasoconstriction, drowsiness, dizziness and rebound headache.

References[edit]

^ ^a ^b Sanders SW, Haering N, Mosberg H, Jaeger H. Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. Eur J Clin Pharmacol 1983; 30: 331–4.
^ ^a ^b ^c ^d Tfelt-Hansen P, Johnson ES. Ergotamine. In: Olesen J, Tfelt-Hansen P, Welch KM, editors. The headaches. New York: Raven Press; 1993. p. 313–22.
^ Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers. Br J Clin Pharmacol 1983; 16: 695–9.
^ AJ Giannini, AE Slaby. Drugs of Abuse. Oradell, NJ, Medical Economics Books, 1989.
^ Walkembach J, Brüss M, Urban BW, Barann M (October 2005). "Interactions of metoclopramide and ergotamine with human 5-HT3A receptors and human 5-HT reuptake carriers". Br. J. Pharmacol. 146 (4): 543–52. doi:10.1038/sj.bjp.0706351. PMC 1751187. PMID 16041395.
^ Tfelt-Hansen P, Saxena PR, Dahlof C, Pascual J, Lainez M, Henry P, Diener H, Schoenen J, Ferrari MD, Goadsby PJ (2000). "Ergotamine in the acute treatment of migraine: a review and European consensus". Brain 123: 9–18. doi:10.1093/brain/123.1.9. PMID 10611116.
^ Pharmacognosy of Ergot
^ Schardl CL, Panaccione DG, Tudzynski P (2006). "Ergot alkaloids--biology and molecular biology". Alkaloids Chem. Biol. The Alkaloids: Chemistry and Biology 63: 45–86. doi:10.1016/S1099-4831(06)63002-2. ISBN 978-0-12-469563-4. PMID 17133714.
^ AJ Giannini. Biological Foundations of Clinical Psychiatry. Oradell, NJ. Medical Economics Puclishing Co., 1986.
^ "Cafergot FDA Information". Retrieved 2012-01-25.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 成人における片頭痛の急性期治療 acute treatment of migraine in adults
2. 小児における片頭痛の急性期治療 acute treatment of migraine in children
3. 薬物乱用頭痛：治療および予後 medication overuse headache treatment and prognosis
4. 性行為に伴う一次性頭痛 primary headache associated with sexual activity
5. 薬物乱用頭痛：病因、臨床的特徴、および診断 medication overuse headache etiology clinical features and diagnosis

English Journal

Structure and function of serotonin G protein-coupled receptors.

McCorvy JD1, Roth BL1.
Pharmacology & therapeutics.Pharmacol Ther.2015 Jun;150:129-142. doi: 10.1016/j.pharmthera.2015.01.009. Epub 2015 Jan 17.
Serotonin receptors are prevalent throughout the nervous system and the periphery, and remain one of the most lucrative and promising drug discovery targets for disorders ranging from migraine headaches to neuropsychiatric disorders such as schizophrenia and depression. There are 14 distinct seroton
PMID 25601315

GR-127935-sensitive Mechanism Mediating Hypotension in Anesthetized Rats: Are 5-HT5B Receptors Involved?

Sánchez-Maldonado C1, López-Sánchez P, Anguiano-Robledo L, Leopoldo M, Lacivita E, Terrón JA.
Journal of cardiovascular pharmacology.J Cardiovasc Pharmacol.2015 Apr;65(4):335-41. doi: 10.1097/FJC.0000000000000200.
The 5-HT1B/1D receptor antagonist, GR-127935, inhibits hypotensive responses produced by the 5-HT1A, 5-HT1B/1D and 5-HT7 receptor agonist, and 5-HT5A/5B receptor ligand, 5-carboxamidotryptamine (5-CT), in rats. This work further characterized the above mechanism using more selective 5-HT1B and 5-HT1
PMID 25502305

Ergotamine and nicergoline - facts and myths.

Zajdel P1, Bednarski M2, Sapa J2, Nowak G3.
Pharmacological reports : PR.Pharmacol Rep.2015 Apr;67(2):360-3. doi: 10.1016/j.pharep.2014.10.010. Epub 2014 Oct 30.
Ergotamine, being a representative of naturally occurring ergoline alkaloids, derived from d-lysergic acid, and nicergoline, a d-lumilysergic acid derivative belonging to semi-synthetic ergot-derived alkaloids, display diversified affinity for adrenergic, serotoninergic, and dopamine receptors. Alth
PMID 25712664

Japanese Journal

麦角剤による薬剤性無菌性髄膜炎の1例

臨床神経学 55(6), 421-423, 2015
NAID 130005083887

ドイツ語圏の片頭痛研究史 : 1. 交感神経血管説

自律神経 = The Autonomic nervous system 46(6), 544-550, 2009-12-15
NAID 10026904695

耳介側頭神経ブロックと後頭環椎関節ブロックの併用が奏効した群発頭痛の1症例

日本ペインクリニック学会誌 13(2), 118-121, 2006
NAID 130004085878

Related Pictures

★リンクテーブル★

リンク元	「エルゴタミン」「酒石酸エルゴタミン」
関連記事	「tartrate」

「エルゴタミン」

Ergotamine
Systematic (IUPAC) name
	(6aR,9R)-N-((2R,5S,10aS,10bS)- 5-benzyl-10b-hydroxy-2-methyl- 3,6-dioxooctahydro-2H-oxazolo[3,2-a] pyrrolo[2,1-c]pyrazin-2-yl) -7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg] quinoline-9-carboxamide
Clinical data
Trade names	Cafergot, Ergomar
AHFS/Drugs.com	monograph
Pregnancy cat.	X (US)
Legal status	Prescription Only (S4) (AU) POM (UK) ℞-only (US)
Routes	Oral
Pharmacokinetic data
Bioavailability	Intravenous: 100%,; Intramuscular: 47%,; Oral: <1% (Enhanced by co-administration of caffeine )
Metabolism	Hepatic
Half-life	2 hours
Excretion	90% biliary
Identifiers
CAS number	113-15-5
ATC code	N02CA02
PubChem	CID 8223
IUPHAR ligand	149
DrugBank	DB00696
ChemSpider	7930
UNII	PR834Q503T
KEGG	D07906
ChEBI	CHEBI:64318
ChEMBL	CHEMBL442
Chemical data
Formula	C33H35N5O5
Mol. mass	581.66 g/mol
	SMILES O=C3N1CCC[C@H]1[C@]2(O)O[C@](C(=O)N2[C@H]3Cc4ccccc4)(NC(=O)[C@@H]8/C=C7/c5cccc6c5c(cn6)C[C@H]7N(C)C8)C;
	InChI InChI=1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1 ; Key:XCGSFFUVFURLIX-VFGNJEKYSA-N ;
(what is this?) (verify);